GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Net Interest Income

Vanda Pharmaceuticals (FRA:VM4) Net Interest Income : €0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Vanda Pharmaceuticals's net interest income for the three months ended in Mar. 2024 was €0.0 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Vanda Pharmaceuticals Net Interest Income Historical Data

The historical data trend for Vanda Pharmaceuticals's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Net Interest Income Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vanda Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vanda Pharmaceuticals Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Net Interest Income Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals (FRA:VM4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Net Interest Income
Comparable Companies
NKTR VTYX AVIR SLDB QTTB FHTX MRSN XOMA REPL PSTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
VNDA:USA VM4:Germany
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Website
https://www.vandapharma.com
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines